|
2014 SPONSOR |
Otsuka Pharmaceutical Co., Ltd. is engaged in the research and development, manufacture, and sale of innovative, creative products. Hopeful that the products we create will aid the treatment of disease and contribute to day-to-day well-being.
Booth No. E022
Exhibition Item
Pletaal (cilostaol) is a quinilinone-derivative medication used in the alleviation of the symptom of intermittent claudication in worldwide and used for prevention of 2nd stroke in some Asian countrie |
|
Otsuka Pletaal Luncheon Symposium |
Organized by CVRF and Supported by Educational Grant from Korea Otsuka Pharmaceutical Co., Ltd. |
Thursday, April 24
12:45 PM - 1:45 PM
Room 4-1, Level 4 |
Moderator(s): Tae Hoon Ahn, Seung-Woon Rha | Panelist(s): Sung-Ho Her, Jae-Hwan Lee | | Optimal Antiplatelet Therapy for Symptomatic PAD |
12:45 PM |
The Role of PAQ (Peripheral Artery Questionnaire)
Lecturer : Kyoung Im Cho
|
1:00 PM |
Medical Treatment of Symptomatic PAD: The Role of Cilostazol
Lecturer : Seung-Whan Lee
|
1:15 PM |
Medical Treatment After Endovascular Therapy: Focus on STOP-IC
Lecturer : Hiroyoshi Yokoi
|
1:30 PM |
Discussion
|
|
|
|
|
|
|
|
|
|
CardioVascular Research Foundation(CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
Tel: 82-2-3010-7255/ Business registration number: 215-82-06387
Copyright ¨Ï 2002 CVRF, Seoul, Korea. All rights reserved. |
|
|
|